A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...